Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis

Table 1

Baseline characteristics and quality assessment of the included studies.

Study	Year	Location	Sample size	Type	Metastasis	Follow-up	Gender (m/f)	Treatment	Outcomes	Inflammatory markers
Funovics et al. [18]	2011	Austria	79	Osteosarcoma	30/49	33 (1-126) months	42/37	Chemotherapy; surgery	DPS/OS	CRP
Nakamura et al. [19]	2013	British	318	Osteosarcoma; Ewing’s sarcoma; chondrosarcoma	NO	40 (1-109) months	176/142	Radiotherapy; surgery; chemotherapy	OS	CRP
Liu et al. [20]	2015	China	327	Osteosarcoma	130/197	24 (3-60) months	235/92	Surgery; chemotherapy	OS	LMR
Liu et al. [10]	2016	China	162	Osteosarcoma	78/162	NA	96/66	Chemotherapy; surgery	OS	CRP, GPS, LMR, NLR, PLR
Aggerholm-Pedersen et al. [21]	2016	Denmark	172	Chondrosarcoma; Ewing’s sarcoma; osteosarcoma	NO	8.8 (4.3-19) years	98/74	Radiotherapy; surgery; chemotherapy	DPS/OS	CRP, GPS, NLR
Xia et al. [11]	2016	China	359	Osteosarcoma	132/227	40 (3-60) months	258/101	Surgery; chemotherapy	OS	NLR, PLR,
Li et al. [22]	2017	China	215	Osteosarcoma	30/49	NA	122/94	Surgery; chemotherapy	OS	GPS, NLR, PLR
Li et al. [13]	2015	China	85	Osteosarcoma	37/85	NA	43/42	Chemotherapy	OS	CRP
Jettoo et al. [23]	2019	British	79	Osteosarcoma; chondrosarcoma; Ewing’s sarcoma	14/63	45 (1-172) months	44/35	Surgery; chemotherapy	DPS/OS	CRP
Huang et al. [24]	2018	China	103	Osteosarcoma	13/90	43 months	63/40	Surgery; chemotherapy	OS	GPS, NLR
Huang et al. [12]	2019	China	126	Osteosarcoma	7/119	44 (7-81) months	78/48	Surgery; chemotherapy	OS	NLR, PLR
Hu et al. [25]	2020	China	137	Osteosarcoma	61/76	55 (4-112) months	80/57	Surgery; chemotherapy	OS	LMR

Note: “” median (minimum-maximum) follow-up time; NA: data were not provided in the publication.